The Pharma Data

OCTOBER 14, 2020

15, 2020 /PRNewswire/ — Armata Pharmaceuticals , Inc. Patrick , Chief Executive Officer of Armata Pharmaceuticals. About Armata Pharmaceuticals, Inc. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing. .

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Drugs 52

The Pharma Data

JANUARY 27, 2021

28, 2021 /PRNewswire/ — CASI Pharmaceuticals (Formerly Known As EntreMed, Inc.). About CASI Pharmaceuticals. CASI Pharmaceuticals, Inc. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals ( China ) Co., and BEIJING , Jan.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

The Pharma Data

JANUARY 13, 2021

Fast Track designation facilitates the development and expedites the review of drugs that are intended to treat serious and life-threatening conditions and show the potential to fill an unmet medical need. A preprint supporting Brilacidin’s COVID-19 treatment potential can be downloaded at the link below. Source link.

Clinical Trials 52

Clinical Trials Trials Treatment Pharmaceuticals 52

The Pharma Data

JANUARY 26, 2021

27, 2021 /PRNewswire/ — Armata Pharmaceuticals , Inc. About Armata Pharmaceuticals, Inc. In addition, in collaboration with Merck, known as MSD outside of the United States and Canada , Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Production 52

Perficient: Drug Development

JANUARY 4, 2024

With a team of more than 300 AI professionals, including data scientists, data engineers, AI architects, and AI developers, Perficient has extensive knowledge and skills in various AI domains.  Download the Forrester report,  The AI Services Landscape, Q1 2024   to learn more (available to Forrester subscribers and for purchase).

Engineering 72

Engineering Pharmaceuticals Production Research 72

The Pharma Data

JANUARY 7, 2021

To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: CEO Laurie Heilmann will be presenting the strategic roadmap for accelerating growth of tech-enabled drug discovery in cancer. Click image above to view full announcement.

Pharmaceutical Companies 52

Pharmaceutical Companies Therapies Science Pharmaceuticals 52

Conversations in Drug Development Trends

MARCH 7, 2024

When conducting first-in-human (FIH) clinical trials, small to midsize pharmaceutical and biotechnology companies are faced with several crucial choices that can shape the trajectory of their drug development pathway. For additional insights, download our full white paper, “ First-in-Human Studies: IND or CTA? ”.

Clinical Trials 52

Clinical Trials Trials FDA Drug Development 52

Conversations in Drug Development Trends

APRIL 15, 2024

As the clinical research landscape continually evolves, the choice of a Contract Research Organization (CRO) partner can significantly impact the success of drug development programs. Discover how Worldwide is positioned to meet your needs with agility, expertise, and a truly personalized approach.

Clinical Trials 52

Clinical Trials Clinical Development Clinical Research Pharmaceutical Companies 52

The Pharma Data

JANUARY 13, 2021

. Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer. Mr. Barrow has over a decade of experience leading drug development programs aimed at identifying and testing novel treatments in a wide range of disease conditions under FDA and EMA.

Clinical Trials 52

Clinical Trials FDA Trials Production 52

The Pharma Data

JANUARY 20, 2021

” “Dynacure is a leader in rare disease drug development, as evidenced by its lead product candidate DYN101, which is in clinical development for the treatment of Myotubular and Centronuclear Myopathies for which there are no FDA or EMA approved therapeutics,” said Ms. Previously, Ms. Prior to Merrimack, Ms.

Treatment 40

Treatment Pharmaceuticals Drug Development Science 40

Metabolite Tales Blog

NOVEMBER 17, 2022

Roquinimex (Linomide), a drug developed by Pfizer for the treatment of multiple sclerosis, is structurally related to laquinimod. Figure 3: Roquinimex (linomide) Clinical development of both laquinimod and roquinimex was halted due to serious cardiovascular events. Teva Pharmaceuticals licensed laquinimod from Active Biotech.

International 52

International Licensing Licensing Treatment 52

The Pharma Data

DECEMBER 28, 2020

Our new directors are well-recognized for their leadership and accomplishments in the biopharmaceutical, biotechnology and pharmaceutical industries, as well as in public capital markets and corporate governance.” Russell served as a director of Endocyte, a Nasdaq-listed public company acquired by Novartis, and AMAG Pharmaceuticals.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Government Therapies 52

The Pharma Data

DECEMBER 28, 2020

Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Annamycin for treatment of soft tissue sarcomas. .

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

DECEMBER 28, 2020

She most recently comes from a position as Senior Medical Director at Ferring Pharmaceuticals in Copenhagen. Dr Reimer will replace Dr Charlotte Russel and be overall medically responsible for Alligator’s drug development candidates, with an emphasis on bringing mitazalimab and ATOR-1017 into Phase II efficacy studies.

Clinical Development 40

Clinical Development Doctors Drug Development International 40

The Pharma Data

NOVEMBER 1, 2020

who brings to the Company over 25 years of neuroscience leadership experience in the pharmaceutical and biotech industries, including most recently as Chief Operating Officer of Therachon Holding AG until its acquisition by Pfizer in July 2019. View original content to download multimedia: [link]. SOURCE Corlieve Therapeutics.

Therapies 52

Therapies Science Treatment Disease 52

The Pharma Data

NOVEMBER 10, 2020

Dr. Liu shared his over 30 years of R&D experience in drug development both in the global pharmaceutical companies and world renowned scientific research institutions. By joining Innovent, Dr. Liu will be responsible for global R & D, pipeline strategy, business development and international operations.

Biosimilars 52

Biosimilars Clinical Trials International Clinical Development 52

The Pharma Data

NOVEMBER 26, 2020

As drug molecules become more complex so do the options to deliver them. This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. HELSINKI , Nov. ” Prof.

Small Molecule 52

Small Molecule Clinical Trials Marketing Pharmaceuticals 52

The Pharma Data

DECEMBER 8, 2020

8, 2020 /PRNewswire/ — At its Investor Day yesterday, Ionis Pharmaceuticals, Inc. ” Dr. Monia continued, “For years we have been recognized for our excellence in research, early drug development and scientific innovation. About Ionis Pharmaceuticals, Inc. SOURCE Ionis Pharmaceuticals, Inc.

RNA 52

RNA Pharmaceuticals Disease Treatment 52

PPD

JULY 13, 2023

At the beginning of 2023, the PPD clinical research business of Thermo Fisher Scientific surveyed 120 drug developers across the pharmaceutical, biopharmaceutical and biotechnology sectors (referred to collectively as “pharma”) to learn more about sponsors’ current needs for site and patient recruitment services.

Clinical Trials 52

Clinical Trials Pharma Companies Trials Clinical Research 52

Perficient: Drug Development

JULY 11, 2023

Perficient is listed as a medium-sized consultancy with our industry focus being industrial products, pharmaceuticals and medical equipment, and retail. To find out more, download the Forrester Commerce Services Landscape, and contact our commerce experts today.

Marketing 40

Marketing Pharmaceuticals Production Research 40

PPD

JULY 9, 2024

Drug developers need to staff RA teams that can handle regular lifecycle maintenance ebbs and flows across lifecycle maintenance tasks, and plan for a workload that sometimes requires senior-level expertise, while at other times is much more suited to support staff. However, completing this work is only half the challenge.

Compliance 52

Compliance Production Clinical Research Marketing 52

The Pharma Data

JANUARY 17, 2021

18 , 2021 /PRNewswire/ — Hanmi Pharmaceutical Co., plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields.

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

Drug Channels

NOVEMBER 2, 2020

Drug Channels readers will save $200 off the standard rate when they use code ZZX688 and register prior to November 13th.*. You can download the complete agenda here. Visit www.raredisease-summit.com for further details and to register. David Fajgenbaum, M.D., Visit www.raredisease-summit.com for further details and to register.

Disease 52

Disease FDA Pharmaceuticals Hospitals 52

The Pharma Data

JANUARY 25, 2021

patent is part of a patent family, exclusively licensed from Ionis Pharmaceuticals, which covers modulators of DNM2 expression. The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drug candidates. View original content to download multimedia: [link].

Treatment 40

Treatment Disease Pharmaceuticals FDA 40

DrugBank

NOVEMBER 25, 2024

The pharmaceutical industry stands at an exciting crossroads, with groundbreaking innovations in drug discovery and delivery redefining what’s possible in patient care. Innovating Beyond Challenges: Emerging Therapies and Technologies The evolution of drug delivery systems tells a compelling story of human ingenuity.

Drugs 52

Drugs Therapies Pharmaceuticals Vaccine 52

Codon

FEBRUARY 13, 2024

The weakened dose of phages helped bacteria develop resistance, and the trial became yet another study that provided evidence phages are safe, but little more. Phages that can be essentially downloaded and synthesized by anyone, in any location, would solve those problems, he says. 4 But the same barriers still exist today. .

Therapies 135

Therapies Virus DNA Clinical Trials 135

The Pharma Data

NOVEMBER 4, 2020

Pharmaceutical, biotechnology and medical device companies have been uniquely impacted by the Covid-19 pandemic, posing both opportunities and challenges for the life sciences industry. Source link.

Science 52

Science Clinical Trials Therapies Laboratories 52

The Pharma Data

DECEMBER 15, 2020

TOMI-T1D is an international partnership between academia, the pharmaceutical industry and nonprofit organizations. The project also seeks to engage the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to identify opportunities for regulatory endorsement of such drug development tools.

Drug Development 40

Drug Development Clinical Trials Trials Vaccine 40

Fierce BioTech

MARCH 7, 2025

Unlocking the Potential of Biocatalysis The pharmaceutical industry is evolving, and biocatalysis is at the forefront of this transformation. Access our comprehensive guide to learn how drug manufacturers can create more sustainable, cost-effective, and efficient production processes by harnessing natures catalystsenzymes and cells.

Pharmaceuticals 52

Pharmaceuticals Drug Development Production Drugs 52

Drug Target Review

MARCH 13, 2025

Planning the journey from data to deliverables The future of AI-enabled drug development benefits from the continued advancement of multimodality and clinical genomics, with a focus on integration, efficiency and personalisation to transform both care and R&D.

Drug Development 59

Drug Development Science Clinical Trials FDA 59